Replimune Group (NASDAQ:REPL) Shares Cross Above Fifty Day Moving Average – Time to Sell?

Replimune Group, Inc. (NASDAQ:REPL) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $13.46 and traded as high as $16.75. Replimune Group shares last traded at $16.06, with a volume of 7,281,109 shares trading hands.

Analyst Upgrades and Downgrades

REPL has been the subject of a number of analyst reports. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. JPMorgan Chase & Co. upped their price objective on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, August 26th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Finally, Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Replimune Group Price Performance

The company’s 50 day moving average price is $13.46 and its 200 day moving average price is $9.25. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -5.10 and a beta of 0.93.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. On average, equities research analysts predict that Replimune Group, Inc. will post -2.82 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Andrew Schwendenman sold 7,632 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $98,987.04. Following the completion of the sale, the chief accounting officer owned 99,425 shares of the company’s stock, valued at approximately $1,289,542.25. This trade represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of Replimune Group stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the transaction, the chief executive officer owned 708,151 shares of the company’s stock, valued at $9,184,718.47. This trade represents a 5.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock valued at $1,038,364 over the last three months. 5.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently bought and sold shares of REPL. Essential Partners LLC increased its holdings in shares of Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares in the last quarter. Allworth Financial LP acquired a new stake in shares of Replimune Group during the second quarter worth about $62,000. Legal & General Group Plc bought a new position in shares of Replimune Group during the 2nd quarter valued at about $85,000. WINTON GROUP Ltd bought a new position in shares of Replimune Group during the 2nd quarter valued at about $115,000. Finally, E Fund Management Co. Ltd. bought a new position in shares of Replimune Group during the 2nd quarter valued at about $119,000. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.